It’s war on vaccines. It is an open struggle between Europe and Big Pharma on contracts, there is no team and the responsibilities are less and less clear. Clearly only the daily tension of less and less exciting announcements reigns on the arrival of doses from large manufacturing multinationals.
The last, in order of time, which worries Brussels a lot, is that of Johnson & Johnson, considered the vaccine of the turning point thanks to the single-dose vial and easy storage. The problem is that the pharmaceutical giant, just on the eve of the approval by the EMA, expected for today, has announced that it will not guarantee the delivery of the 55 million vials scheduled for the second quarter of the year.
True, he then took a step back, reassuring to remain “committed to deliveries of 200 million doses for 2021”. Ma too little for the European Commission, given that the company, in this way, guarantees the annual target, but not the one from April to June, crucial in this phase of vaccine shortage.
The relationship with AstraZeneca is no better, which delivered just 10% of the expected doses. In the wake of what Draghi did last week, and governs are ready to reject any new export request in agreement with Brussels which in turn is preparing to extend the operation of the export control system.
In fact, a common thought is that the Anglo-Swedish company is keeping significant quantities of its vaccine in stock waiting for the EU export control mechanism to expire, to then sell it outside the continent.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
